EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical Outcomes of Gradual Corticosteroid Tapering for Immune Checkpoint Inhibitor‐Induced Liver Injury

Naoto Soma, Yoshihito Uchida iD, Kayoko Sugawara, Masamitsu Nakao iD, Nobuaki Nakayama iD, Yukinori Imai, Suguru Mizuno iD, Satoshi Mochida iD

Hepatology Research · 14.08.2026

DOI: 10.1111/hepr.70259 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 14.08.2026. Verfasst von Naoto Soma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology & Hepatology, Faculty of Medicine, Saitama Medical University, Moroyama, Japan. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Immune checkpoint inhibitor (ICI)‐induced liver injury is a clinically important adverse event that may lead to interruption of anticancer therapy. Although systemic corticosteroids are recommended for severe cases, the optimal corticosteroid tapering strategy for relapse prevention and subsequent ICI rechallenge has not been established. We evaluated the clinical outcomes of an empirical institutional gradual corticosteroid tapering strategy developed with reference to Japanese AIH management.

Methods

We retrospectively analyzed 36 consecutive patients with grade ≥ 3 ICI‐induced liver injury. Prednisolone (PSL) was generally initiated at 0.8 mg/kg/day and tapered gradually at a rate of 5 mg every 2 weeks. Steroid pulse therapy was selectively administered in patients with severe liver injury with signs of liver failure. The primary endpoint was relapse during corticosteroid tapering.

Results

Liver injury improved in 35 of 36 patients (97%). The median duration required to taper PSL to ≤ 10 mg/day was 73 (range, 50–168) days. Relapse during corticosteroid tapering occurred in only 1 patient (3%), and no patients required additional immunosuppressive therapy, including mycophenolate mofetil. ICI rechallenge was performed in 13 patients, including 6 with prior CTCAE grade 4 liver injury, and recurrence after rechallenge occurred in only 1 patient (8%). Histopathological findings were characterized predominantly by lobular inflammation with CD8‐positive T‐cell infiltration, whereas classical autoimmune hepatitis‐associated features were relatively limited.

Conclusions

An empirical gradual corticosteroid tapering strategy developed with reference to Japanese AIH management may contribute to relapse prevention and facilitate ICI rechallenge in patients with ICI‐induced liver injury.

Schlagwörter

Stichwörter der Autor:innen

ICI rechallengeICI‐induced liver injurygradual corticosteroid taperingrelapse prevention

Autor:innen und Institutionen

  • Department of Gastroenterology & Hepatology, Faculty of Medicine, Saitama Medical University, Moroyama, Japan.

ORCID-Profile: Yoshihito Uchida, Masamitsu Nakao, Nobuaki Nakayama, Suguru Mizuno, Satoshi Mochida

Zitieren

APA

Soma, N., Uchida, Y., Sugawara, K., Nakao, M., Nakayama, N., Imai, Y., Mizuno, S., & Mochida, S. (2026). Clinical Outcomes of Gradual Corticosteroid Tapering for Immune Checkpoint Inhibitor‐Induced Liver Injury. Hepatology Research. https://doi.org/10.1111/hepr.70259

Vancouver

Soma N, Uchida Y, Sugawara K, Nakao M, Nakayama N, Imai Y, et al. Clinical Outcomes of Gradual Corticosteroid Tapering for Immune Checkpoint Inhibitor‐Induced Liver Injury. Hepatology Research. 2026. doi:10.1111/hepr.70259

BibTeX
@article{Soma2026,
  author = {Soma, Naoto and Uchida, Yoshihito and Sugawara, Kayoko and Nakao, Masamitsu and Nakayama, Nobuaki and Imai, Yukinori and Mizuno, Suguru and Mochida, Satoshi},
  title = {Clinical Outcomes of Gradual Corticosteroid Tapering for Immune Checkpoint Inhibitor‐Induced Liver Injury},
  journal = {Hepatology Research},
  year = {2026},
  doi = {10.1111/hepr.70259}
}
Kostenlos starten →